ARTICLE | Clinical News
Jinarc tolvaptan regulatory update
March 9, 2015 7:00 AM UTC
Otsuka said Health Canada approved Jinarc tolvaptan to treat autosomal dominant polycystic kidney disease (ADPKD). The company expects to launch the vasopressin 2 (V2) receptor antagonist in Canada i...